SGLT2 Inhibition to Address the Unmet Needs in Diabetic Nephropathy

Overview

Journal Diabetes Metab Res Rev

Specialty Endocrinology

Date 2019 Apr 19

PMID 30997935

Citations 16

Authors

Federica Barutta

Sara Bernardi

Giuseppe Gargiulo

Marilena Durazzo

Gabriella Gruden

Affiliations

Soon will be listed here.

Abstract

Current treatment of diabetic nephropathy is effective; however, substantial gaps in care still remain and new therapies are urgently needed to reduce the global burden of the complication. Desirable properties of an "ideal" new drug should include primary prevention of microalbuminuria, additive/synergistic anti-proteinuric effect in combination therapy with renin angiotensin system blockers, reduction of chronic kidney disease progression to lower the risk of end-stage renal disease, and cardiovascular protection. Growing evidence suggests that sodium-glucose cotransporter 2 inhibitors (SGLT2i) may fulfil many of these criteria and represent novel tools to cover the unmet needs in diabetic nephropathy care. However, the underlying mechanisms of SGLT2i renal benefits are still poorly understood and promising results from cardiovascular outcome trials with SGLT2i need confirmation in dedicated renal outcome trials.

Citing Articles

Renal protective effect of ellipticine against streptozotocin induced diabetic nephropathy in rats via suppression of oxidative stress and inflammatory mediator.

Li J, Xie Y, Sun J, Bai F, Althaf Hussain S, Gangireddygari V Acta Cir Bras. 2023; 38:e385623.

PMID: 38055383 PMC: 10695187. DOI: 10.1590/acb385623.

Impact of sodium-glucose cotransporter-2 inhibitors on kidney outcomes in type 2 diabetes: A tertiary center experience.

Tawhari M, Aldahash R, Almutairi F, Albogami M, Rokon A, Alsomali F J Family Community Med. 2023; 30(4):267-272.

PMID: 38044971 PMC: 10688587. DOI: 10.4103/jfcm.jfcm_111_23.

Comparative safety of sodium-glucose co-transporter 2 inhibitors in elderly patients with type 2 diabetes mellitus and diabetic kidney disease: a systematic review and meta-analysis.

Liu Y, An C, Liu P, Yang F, Zhao Q Ren Fail. 2023; 45(1):2217287.

PMID: 37246403 PMC: 10228313. DOI: 10.1080/0886022X.2023.2217287.

Autophagy and its therapeutic potential in diabetic nephropathy.

Han Y, Liu L, Yan J, Chen M, Meng X, Zhou X Front Endocrinol (Lausanne). 2023; 14:1139444.

PMID: 37020591 PMC: 10067862. DOI: 10.3389/fendo.2023.1139444.

Protective Effects of Rifampicin and Its Analog Rifampicin Quinone in a Mouse Model of Obesity-Induced Type 2 Diabetes.

Garg A, Alam M, Bai S, Dandawate M, Kumari N, Gupta S ACS Pharmacol Transl Sci. 2023; 6(2):253-269.

PMID: 36798477 PMC: 9926524. DOI: 10.1021/acsptsci.2c00082.

References

Wang X, Levi J, Luo Y, Myakala K, Herman-Edelstein M, Qiu L . SGLT2 Protein Expression Is Increased in Human Diabetic Nephropathy: SGLT2 PROTEIN INHIBITION DECREASES RENAL LIPID ACCUMULATION, INFLAMMATION, AND THE DEVELOPMENT OF NEPHROPATHY IN DIABETIC MICE. J Biol Chem. 2017; 292(13):5335-5348. PMC: 5392679. DOI: 10.1074/jbc.M117.779520. View

Heerspink H, Kosiborod M, Inzucchi S, Cherney D . Renoprotective effects of sodium-glucose cotransporter-2 inhibitors. Kidney Int. 2018; 94(1):26-39. DOI: 10.1016/j.kint.2017.12.027. View

Perkovic V, de Zeeuw D, Mahaffey K, Fulcher G, Erondu N, Shaw W . Canagliflozin and renal outcomes in type 2 diabetes: results from the CANVAS Program randomised clinical trials. Lancet Diabetes Endocrinol. 2018; 6(9):691-704. DOI: 10.1016/S2213-8587(18)30141-4. View

Pavkov M, Knowler W, Lemley K, Mason C, Myers B, Nelson R . Early renal function decline in type 2 diabetes. Clin J Am Soc Nephrol. 2011; 7(1):78-84. PMC: 3265342. DOI: 10.2215/CJN.07610711. View

Zelniker T, Wiviott S, Raz I, Im K, Goodrich E, Bonaca M . SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet. 2018; 393(10166):31-39. DOI: 10.1016/S0140-6736(18)32590-X. View

Abdul-Ghani M, DeFronzo R . Lowering plasma glucose concentration by inhibiting renal sodium-glucose cotransport. J Intern Med. 2014; 276(4):352-63. PMC: 5785085. DOI: 10.1111/joim.12244. View

Cassis P, Locatelli M, Cerullo D, Corna D, Buelli S, Zanchi C . SGLT2 inhibitor dapagliflozin limits podocyte damage in proteinuric nondiabetic nephropathy. JCI Insight. 2018; 3(15). PMC: 6129124. DOI: 10.1172/jci.insight.98720. View

Zhang Y, Thai K, Kepecs D, Gilbert R . Sodium-Glucose Linked Cotransporter-2 Inhibition Does Not Attenuate Disease Progression in the Rat Remnant Kidney Model of Chronic Kidney Disease. PLoS One. 2016; 11(1):e0144640. PMC: 4711803. DOI: 10.1371/journal.pone.0144640. View

Wiviott S, Raz I, Bonaca M, Mosenzon O, Kato E, Cahn A . Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2018; 380(4):347-357. DOI: 10.1056/NEJMoa1812389. View

10.

Wanner C, Inzucchi S, Lachin J, Fitchett D, von Eynatten M, Mattheus M . Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes. N Engl J Med. 2016; 375(4):323-34. DOI: 10.1056/NEJMoa1515920. View

11.

Wanner C, Inzucchi S, Zinman B . Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes. N Engl J Med. 2016; 375(18):1801-2. DOI: 10.1056/NEJMc1611290. View

12.

Skrtic M, Yang G, Perkins B, Soleymanlou N, Lytvyn Y, von Eynatten M . Characterisation of glomerular haemodynamic responses to SGLT2 inhibition in patients with type 1 diabetes and renal hyperfiltration. Diabetologia. 2014; 57(12):2599-602. DOI: 10.1007/s00125-014-3396-4. View

13.

Lytvyn Y, Skrtic M, Yang G, Yip P, Perkins B, Cherney D . Glycosuria-mediated urinary uric acid excretion in patients with uncomplicated type 1 diabetes mellitus. Am J Physiol Renal Physiol. 2014; 308(2):F77-83. DOI: 10.1152/ajprenal.00555.2014. View

14.

Davies M, DAlessio D, Fradkin J, Kernan W, Mathieu C, Mingrone G . Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2018; 41(12):2669-2701. PMC: 6245208. DOI: 10.2337/dci18-0033. View

15.

Ferrannini E, Mark M, Mayoux E . CV Protection in the EMPA-REG OUTCOME Trial: A "Thrifty Substrate" Hypothesis. Diabetes Care. 2016; 39(7):1108-14. DOI: 10.2337/dc16-0330. View

16.

Nadkarni G, Ferrandino R, Chang A, Surapaneni A, Chauhan K, Poojary P . Acute Kidney Injury in Patients on SGLT2 Inhibitors: A Propensity-Matched Analysis. Diabetes Care. 2017; 40(11):1479-1485. PMC: 5652593. DOI: 10.2337/dc17-1011. View

17.

Umino H, Hasegawa K, Minakuchi H, Muraoka H, Kawaguchi T, Kanda T . High Basolateral Glucose Increases Sodium-Glucose Cotransporter 2 and Reduces Sirtuin-1 in Renal Tubules through Glucose Transporter-2 Detection. Sci Rep. 2018; 8(1):6791. PMC: 5931531. DOI: 10.1038/s41598-018-25054-y. View

18.

Shimazu T, Hirschey M, Newman J, He W, Shirakawa K, Le Moan N . Suppression of oxidative stress by β-hydroxybutyrate, an endogenous histone deacetylase inhibitor. Science. 2012; 339(6116):211-4. PMC: 3735349. DOI: 10.1126/science.1227166. View

19.

Cortes P, Riser B, Zhao X, Narins R . Glomerular volume expansion and mesangial cell mechanical strain: mediators of glomerular pressure injury. Kidney Int Suppl. 1994; 45:S11-6. View

20.

Cai X, Yang W, Gao X, Chen Y, Zhou L, Zhang S . The Association Between the Dosage of SGLT2 Inhibitor and Weight Reduction in Type 2 Diabetes Patients: A Meta-Analysis. Obesity (Silver Spring). 2017; 26(1):70-80. DOI: 10.1002/oby.22066. View